ERBB2 and breast cancer: In 2022, Yi et al. investigated the potential synergistic cardiotoxic effects of combining chest radiotherapy and targeted therapy with trastuzumab (TRZ) in breast cancer patients with overexpression of human epidermal growth factor receptor 2 (HER2).